Author: admin_EIS_

Audigent Ranked Number 79 Fastest-Growing Company In North America On The 2022 Deloitte Technology Fast 500

Posted on by admin_EIS_

Attributes Revenue Growth to Success of Market-Leading Curated Marketplace Products & Innovations in Identity and Data Activation

Audigent, the leading data identity, curation, and activation platform, today announced it ranked 79th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. During the measurement period, Audigent grew 2,153%, making it the second fastest-growing advertising technology company on the list. Audigent placed among the top 16% of all companies and #5 in New York State.

Audigent’s Chief Executive Officer, Drew Stein, credits the company’s next-generation curated marketplace products (SmartPMPs™, ContextualPMPs™, and CognitivePMPs™) and its unique approach to actioning data and identity through the supply path for its rocketship growth.

“Incredibly disruptive changes in how data is actioned across the digital media landscape have created an environment where innovation is not just a ‘nice-to-have,’ but an absolute necessity for survival and growth,” Stein said. “Audigent has been at the forefront of data innovation through its unique product suite and has pioneered a new path forward for robust data activation that is privacy-safe, future-proof and valuable to brands and media agencies looking to drive efficiency and performance.”

Read the full article here.

Biomeme To Launch Portable Sample-To-Answer PCR System, Host-Response Testing

Posted on by admin_EIS_

The pandemic wrought remarkable changes in diagnostics, some of which may improve healthcare for future generations. It also precipitated a dramatic expansion for Philadelphia-based mini PCR instrument and assay developer Biomeme.

The company is now using revenues from CAP and CLIA accredited testing labs it owns to create a sample-to-answer instrument and further differentiate itself through a focus on host-response testing.

Biomeme was founded in 2013 to commercialize a mini PCR system called Franklin. The company debuted a wholly owned subsidiary of testing labs, called One Health Laboratories, in February of 2019, in part to capitalize on the attributes of the Franklin system, according to Jesse vanWestrienen, a Biomeme cofounder and executive VP of products.

“We felt that a lot of the types of products that Biomeme was creating would be really useful in [lab-developed test] environments and would add some capabilities that other CLIA and CAP labs don’t necessarily have,” vanWestrienen said, like mobility and ease of use.

The firm validated a lab-developed respiratory panel for influenza A, influenza B, and respiratory syncytial virus prior to the pandemic.

Then the pandemic hit and there was a dire need for SARS-CoV-2 testing. In May of 2020, Biomeme obtained Emergency Use Authorization for a lab-developed SARS-CoV-2 assay to be run at One Health Labs, and three months later, it received a second EUA for a modified test using the firm’s two-minute manual nucleic acid extraction kit, called the M1 Sample Prep Cartridge, and running on the Franklin or on standard thermal cyclers.

“Then, it was a matter of scaling because obviously, the demand was insane,” vanWestrienen said.

Over the course of the pandemic, One Health Labs has overseen more than 100 temporary testing sites using the Franklin mobile PCR system.

Read the full article here.

What Roundtrip Learned From Two Years Of Internal DEI Audits

Posted on by admin_EIS_

The data has influenced hiring practices, leadership decisions and internal policy, such as removing college degrees as requirements from some jobs.

Company leaders who choose to engage in conversations with their employees about diversity, equity and inclusion strategies know those conversations can feel clumsy or start from an uncomfortable place.

In the wake of the rising Black Lives Matter movement in 2020, Roundtrip founder and CEO Mark Switaj decided it was no longer appropriate for the Callowhill-based company to stay quiet on issues of race or current events. It was more important, he thought, to take a hard look at the company’s hiring and operating practices in order to be as inclusive and representative as possible.

While Switaj said he recognizes that diverse teams are better for business, he also wanted the company to better represent the population the healthcare transportation company serves.

“We wanted to make sure we were telling our story,” the CEO told Technical.ly. “Large tech brands were showing maybe skewed perspectives, but for populations we serve, most of our clients are lower socioeconomic communities and the elderly.”

Read the full article here.

Restor3d Raises $23 Million To Expand 3D Printed Personalized Solutions For Musculoskeletal Surgery And Develop Machine Learning Enabled Design Tools

Posted on by admin_EIS_

restor3d, a leading medical device company and 3D printing manufacturer, has raised $23 million to expand the delivery of 3D printed personalized surgical solutions across multiple musculoskeletal specialties and to develop machine learning software tools for assisting engineers with patient specific implant design.

Ken Gall Ph.D., co-founder of restor3d and a Professor at Duke University, says the company will be deploying the capital on (1) new product introductions and enhanced 3D printed personalized surgical solutions in upper/lower extremity, spine, and trauma, (2) ongoing development of machine learning enabled software for surgical planning and implant design, (3) fundamental research, preclinical, and clinical studies, and (4) expansion of the commercial team to support market traction. In addition, in early 2023, restor3d will move into a new facility in Research Triangle Park that will expand capabilities for patient specific digital design, in-house manufacturing of implants and instruments, as well as surgeon training and education labs.

In 2021, restor3d announced it had merged with Kinos Medical, a leading total ankle replacement company, which helped accelerate restor3d’s expansion into the high-growth extremity arthroplasty markets in the U.S. restor3d has multiple FDA product clearances that span lower extremity, upper extremity, spine, and trauma. The new funding and restor3d’s 3D printed implant and disposable instrument model will enable simultaneous expansion across these diverse markets to provide innovative solutions for pressing clinical needs.

Read the full article here. 

Philadelphia Adtech Startup Sidecar, Backed by $33.5M in Funding, Acquired by New York Competitor

Posted on by admin_EIS_

Philadelphia advertising technology startup Sidecar has been acquired by New York-based competitor Quartile.

The deal closed last week, and the terms were not disclosed. Sidecar will take Quartile’s name, and the company will retain its office at One South Broad in Philadelphia. The acquisition will fold Sidecar’s 180 employees into Quartile, bringing the total headcount to 300.

Quartile CEO Daniel Knijnik will remain chief executive, and Sidecar CEO Andre Golsorkhi will serve as president of the company.

Sidecar is an e-commerce tech firm that uses artificial intelligence to help retailers determine where and how to market their products. It was founded in 2014 with a focus on the e-commerce space for small and large online retailers.

Sidecar raised a total $33.5 million in venture capital before the acquisition. It last raised a $7.5 million round in 2019. Investors included Ben Franklin Technology Partners of Southeastern Pennsylvania, Harbert Growth Partners, Osage Venture Partners, Ascent Venture Partners and Robin Hood Ventures.

Read the full article here.

Houwzer’s Next Move

Posted on by admin_EIS_

As a first grader in Cape May Courthouse, New Jersey, Mike Maher launched his earliest small business: selling Blow Pops and construction paper.

“Back in the day, colored paper was in high demand and kids always like candy, so I thought it was a great way to subsidize my own love of art and candy,” Maher says, laughing at the memory.

Now, as the CEO of Philly-based Houwzer—the five-year-old real estate brokerage firm that’s disrupted the industry both by employing salaried (versus commissioned) brokers, and committing so deeply to doing good that they’re a certified B Corp—Maher is continuing to recognize needs where others miss them, with a deep sense of empathy, hard work and service.

A sound direction

Long moved by Toms Shoes and Warby Parker, Maher knew there was no practical way to introduce a one-for-one model for homes. But reading Richard Rothstein’s The Color of Law and learning more about the demographic that the United Way and others have dubbed ALICE—asset limited, income constrained employed—prompted his latest venture.

Just this month, Houwzer announced a new, nonprofit RiseUp Fund: Starting in 2021, for every home sold, Houwzer will commit $100 to help provide down payment and closing cost assistance to the underserved.

“The mission will be to accelerate the generational, upward mobility of the underserved through homeownership,” Maher says. “We looked at the resources we had: agents in the field who can probably find off-market deals to acquire property; mortgage advisors who can help clients get their credit in good standing; and so on” and figured out how to maximize both for the greater good.

Over the next 12 months, Houwzer expects to do close to 1,500 transactions in the markets it serves—meaning the fund will have, at a minimum, $150,000. But they’ll also invite sellers, who on average save $15,000 by working with Houwzer, to match that $100; that could bring the projected pot to $300,000. They’ll invite employees to donate around the holidays, potentially raising that pot higher still. And while $300,000 can only go so far, imagine what they can do as the company continues to grow.

Read the full article here.

Digital health Company Tridiuum’s CEO on its Pivot to Product and Reducing Suicide Rates

Posted on by admin_EIS_

Center City-based behavioral health company Tridiuum kicked off 2020 by announcing Tuesday it has created a partnership with Washington-based LifeStance Health to improvements patient outcomes and further commit to making suicide “a never event.”

The company is known for its Tridiuum ONE platform, a cloud-based SaaS platform that clinical facilities and patients can use to identify behavioral conditions faster, accelerate access to care, engage patients for feedback and deliver treatment progress tracking. The platform integrates with most electronic health records and health IT software, reported the company, which raised a $9.5 million Series B back in December 2018.

The platform is used within the 24 hours before an appointment or visit with a mental health care professional, as Tridiuum CEO Mark Redlus — a serial tech CEO with a background in health tech and clean energy — told Technical.ly. A patient will fill out a two- to four-minute survey on a tablet before entering a session, and its software quickly identifies the scope of what a patient is presenting with at the time, including suicidal ideation, so the healthcare professional can create a treatment plan.

Read the full article here.

Clutch Platform Powers Wizard World's First Loyalty Program for the Comic Con Crowd

Posted on by admin_EIS_

clutch

The producer of the iconic pop culture conventions enlists a marketing technology innovator to deliver personalized, more memorable experiences for fans.

When it comes to fan loyalty, there’s arguably no more devout group than the multitudes of decked-out fans attending Wizard World Comic Con events each year. Now the iconic tour’s producer, Wizard World, Inc. has teamed with Clutch, a consumer management platform pioneer, to further kindle fan devotion through enhanced, personalized experiences at its comic, sci-fi, and related events.

With its new fan loyalty program, Wizard World will offer exclusive incentives for advanced admission purchases along with options to pre-order photo op and autograph sessions at its pop culture events. The program will also help Wizard World use data insights provided by the Clutch platform to identify a fan’s favorite movies, TV shows, comics, and characters, and deliver customized experiences.

“With a fast-growing list of characters, brands, and celebrities participating in our comic con events, it is crucial to Wizard World and our partners that our offerings match specific fan preferences and deliver exactly what they are most passionate about,” explained John Macaluso, Wizard World CEO. “Clutch’s advanced customer marketing technology gives us keen insight into our fans’ behavior and interests, which allows us to cater to their individual preferences and maximize their experiences at all of our shows across the country.”

“Today’s consumers demand that brands deliver customized, even ‘special’ experiences, regardless of location, product, or scale,” said Chris Jones, Senior Vice President of Business Development for Clutch. “Personalization is critical to every customer-centric business, and it will come naturally for a brand like Wizard World that’s already had tremendous success with experiential marketing. The Clutch-Wizard World team is going to explore fan loyalty, events marketing, and data collection in a way that hasn’t been done before, creating untold growth opportunity for both organizations.”

The loyalty program is planned for full-scale deployment in the first quarter of 2016. In the meantime, you can see the conflux of devotees for yourself at the next Wizard World Comic Con, happening November 20-22 in Reno, Nevada.

About Clutch
Clutch’s advanced Consumer Management platform delivers customer intelligence and personalized engagements empowering consumer-focused brands to identify, understand and motivate their Most Valuable Customers (MVCs). Its advanced marketing platform integrates customer data across point-of-sale, ecommerce, mobile and social channels delivering personalized experiences, intelligent engagements and loyal customers.Headquartered outside of Philadelphia, Clutch’s solutions impact over 55 million consumers of over 750 brands. Clutch is a proud partner of Safeguard Scientifics SFE, +0.47% and Ben Franklin Technology Partners. For more information visit clutch.com, follow Clutch Holdings on LinkedIn or@ClutchSuccess on Twitter.

About Wizard World
Wizard World, Inc. (http://www.wizardworld.com) produces Comic Cons and pop culture conventions across North America that celebrate the best in pop-fi, pop culture, movies, television, cosplay, comics, graphic novels, toys, video gaming, sci-fi, gaming, original art, collectibles, contests and more. A first-class lineup of topical programming takes place at each event, with celebrity Q&A’s, comics-themed sessions, costume contests, movie screenings, evening parties and more. Wizard World has also launched CONtv, a digital media channel in partnership with leading independent content distributor Cinedigm™ (NASDAQ: CIDM), and ComicConBox™, a premium subscription-based monthly box service. Fans can interact with Wizard World on Facebook, Twitter, Pinterest, Instagram and other social media services.

The 2015-16 Wizard World Comic Con schedule is available at: www.wizardworld.com/wizcon.html.

Cagent Vascular Receives $9M Investment to Accelerate Marketing of its Lead Product

Posted on by admin_EIS_

A Wayne medical device company has raised $9 million to accelerate the commercialization of its peripheral artery disease device cleared by the Food and Drug Administration last year.

Cagent Vascular received the investment from Sectoral Asset Management. Marc-Andre Marcotte, a partner and COO at the Canadian investment firm, has joined Cagent’s board of directors.

Founded in 2014, Cagent specializes in developing next generation angioplasty balloons using its proprietary serration technology.

In April 2020, the FDA granted marketing clearance to the company’s Serranator PTA serration balloon catheter — an angioplasty device with serrated metal strips to aid in arterial expansion — for treating below-the-knee lesions.

Cagent intends to use part of the investment proceeds to accelerate the commercialization and scaling of manufacturing for the Serranator product.

Read the full article here.

Biomeme & Predigen Merge to Enable Point-of-Care Delivery of Host Response Tests That Address Critical Unmet Needs in Healthcare

Posted on by admin_EIS_

Biomeme, the leading provider of portable PCR testing solutions, has signed a definitive agreement to acquire Predigen, a privately held diagnostic company and emerging leader in precision medicine focused on host response diagnostics.

Predigen’s acquisition will expand Biomeme’s capabilities across infectious disease and clinical microbiology, business management, and commercialization.

redigen’s portfolio includes flagship host gene expression biomarkers for the pre-symptomatic detection of viral infections as well as biomarkers that accurately discriminate viral from bacterial infections to enable appropriate patient management and antibiotic stewardship. Predigen also has signatures for sepsis diagnosis, sepsis risk stratification, and a pipeline of biomarkers for non-infectious diseases. With nine different patents at various stages of execution, this scientific team has received over $50 million in grant funding from the Department of Defense (DoD), National Institutes of Health (NIH), Department of Veterans Affairs (VA), and Department of Homeland Security (DHS).

According to Brian Best, Predigen’s CEO, “Prior to the pandemic, the over-utilization of antibiotics and increasing antimicrobial resistance were dominant concerns among the infectious disease community. That need still exists and it is a significant market opportunity that requires accurate, near-patient and rapid-result performance capabilities. This merger will enable an end-to-end solution to meet this challenge.”

Read the full article here.

×